Processa Pharmaceuticals, Inc. Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable
Processa Pharmaceuticals, Inc. (PCSA) reported Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable of -$10.71 thousand for the 3-month period ending 2017-06-30, per its 10-Q filed 2017-10-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:NoncontrollingInterestInNetIncomeLossPreferredUnitHoldersRedeemable · last filed 2017-10-04
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for the quarter ending 2017-06-30 was -$10.71K.
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for the quarter ending 2017-03-31 was -$10.59K.
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for the quarter ending 2016-12-31 was -$10.82K.
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for the quarter ending 2016-09-30 was -$10.82K.
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for fiscal 2016 was -$43.06K.
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for fiscal 2015 was -$42.94K, a 102.86% decline from fiscal 2014.
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for fiscal 2014 was $1.50M, a 6955.16% increase from fiscal 2013.
- Processa Pharmaceuticals, Inc. noncontrolling interest in net income (loss) preferred unit holders, redeemable for fiscal 2013 was $21.30K, a 93.53% decline from fiscal 2012.
| Period end | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 3 month | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 3 month as first filed | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 6 month | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 6 month as first filed | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 9 month | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 9 month as first filed | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 12 month | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 12 month as first filed | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 27 month | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 30 month | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 33 month | Noncontrolling Interest in Net Income (Loss) Preferred Unit Holders, Redeemable 36 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | -$10.71K 10-Q · filed 2017-10-04 | -$21.29K 10-Q · filed 2017-10-04 | -$32.12K derived: sum of 3 quarters · filed 2017-10-04 | -$42.94K derived: sum of 4 quarters · filed 2017-10-04 | ||||||||
| 2017-03-31 | -$10.59K 10-Q · filed 2017-10-04 | -$21.41K derived: sum of 2 quarters · filed 2017-10-04 | -$32.24K derived: sum of 3 quarters · filed 2017-10-04 | -$42.94K derived: sum of 4 quarters · filed 2017-10-04 | ||||||||
| 2016-12-31 | -$10.82K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$21.65K derived: sum of 2 quarters · filed 2017-09-25 | -$32.35K derived: sum of 3 quarters · filed 2017-10-04 | -$43.06K 10-K · filed 2017-09-25 | ||||||||
| 2016-09-30 | -$10.82K 10-Q · filed 2017-09-08 | -$21.53K derived: sum of 2 quarters · filed 2017-10-04 | -$32.23K 10-Q · filed 2017-09-08 | -$43.06K derived: sum of 4 quarters · filed 2017-10-04 | ||||||||
| 2016-06-30 | -$10.71K 10-Q · filed 2017-10-04 | -$21.41K 10-Q · filed 2017-10-04 | -$32.23K derived: sum of 3 quarters · filed 2017-10-04 | -$43.06K derived: sum of 4 quarters · filed 2017-10-04 | ||||||||
| 2016-03-31 | -$10.71K 10-Q · filed 2017-10-04 | $10.71K 10-Q · filed 2017-08-07 | -$21.53K derived: sum of 2 quarters · filed 2017-10-04 | -$32.35K derived: sum of 3 quarters · filed 2017-10-04 | -$43.06K derived: sum of 4 quarters · filed 2017-10-04 | |||||||
| 2015-12-31 | -$10.82K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | -$21.65K derived: sum of 2 quarters · filed 2017-09-25 | -$32.35K derived: sum of 3 quarters · filed 2017-09-25 | -$42.94K 10-K · filed 2017-09-25 | $42.94K 10-K · filed 2017-06-19 | |||||||
| 2015-09-30 | -$10.82K 10-Q · filed 2017-09-08 | $10.82K 10-Q · filed 2015-12-01 | -$21.53K derived: sum of 2 quarters · filed 2017-09-08 | -$32.12K 10-Q · filed 2017-09-08 | $32.12K 10-Q · filed 2015-12-01 | $1.38M derived: sum of 4 quarters · filed 2017-09-08 | ||||||
| 2015-06-30 | -$10.71K 10-Q · filed 2017-08-30 | $10.71K 10-Q · filed 2015-08-19 | -$21.30K 10-Q · filed 2017-08-30 | $21.30K 10-Q · filed 2015-08-19 | $1.39M derived: sum of 3 quarters · filed 2017-08-30 | $1.44M derived: sum of 4 quarters · filed 2017-08-30 | ||||||
| 2015-03-31 | $10.59K 10-Q · filed 2017-08-07 | $1.40M derived: sum of 2 quarters · filed 2017-08-07 | $1.45M derived: sum of 3 quarters · filed 2017-08-07 | $1.52M derived: sum of 4 quarters · filed 2017-08-07 | ||||||||
| 2014-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | $1.44M derived: sum of 2 quarters · filed 2017-06-19 | $1.50M derived: sum of 3 quarters · filed 2017-06-19 | $1.50M 10-K · filed 2017-06-19 | ||||||||
| 2014-09-30 | $53.05K 10-Q · filed 2015-12-01 | $114.19K derived: sum of 2 quarters · filed 2015-12-01 | $112.21K 10-Q · filed 2015-12-01 | -$64.56K derived: sum of 4 quarters · filed 2015-12-01 | ||||||||
| 2014-06-30 | $61.13K 10-Q · filed 2015-08-19 | $59.15K 10-Q · filed 2015-08-19 | -$117.61K derived: sum of 3 quarters · filed 2015-08-19 | $96.15K derived: sum of 4 quarters · filed 2015-08-19 | ||||||||
| 2014-03-31 | $38.55K 10-Q · filed 2015-05-15 | -$178.75K derived: sum of 2 quarters · filed 2015-05-15 | $35.01K derived: sum of 3 quarters · filed 2015-05-15 | $76.80K derived: sum of 4 quarters · filed 2015-05-15 | $464.20K 10-Q · filed 2014-05-14 | |||||||
| 2013-12-31 | -$217.29K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | -$3.53K derived: sum of 2 quarters · filed 2015-04-14 | $38.25K derived: sum of 3 quarters · filed 2015-04-14 | $21.30K 10-K · filed 2015-04-14 | $425.65K 10-K · filed 2014-03-27 | |||||||
| 2013-09-30 | $213.76K 10-Q · filed 2014-11-13 | $255.55K derived: sum of 2 quarters · filed 2014-11-13 | $238.60K 10-Q · filed 2014-11-13 | $454.72K derived: sum of 4 quarters · filed 2014-11-13 | $285.72K 10-Q · filed 2013-11-08 | |||||||
| 2013-06-30 | $41.79K 10-Q · filed 2014-08-19 | $83.11K 10-Q · filed 2014-08-19 | $240.96K derived: sum of 3 quarters · filed 2014-08-19 | $330.67K derived: sum of 4 quarters · filed 2014-08-19 | $243.18K 10-Q/A · filed 2013-09-06 | |||||||
| 2013-03-31 | $98.94K 10-Q · filed 2014-05-14 | $199.17K derived: sum of 2 quarters · filed 2014-05-14 | $288.88K derived: sum of 3 quarters · filed 2014-05-14 | $358.50K derived: sum of 4 quarters · filed 2014-05-14 | ||||||||
| 2012-12-31 | $100.23K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $189.94K derived: sum of 2 quarters · filed 2014-03-27 | $259.55K derived: sum of 3 quarters · filed 2014-03-27 | $329.17K 10-K · filed 2014-03-27 | ||||||||
| 2012-09-30 | $89.70K 10-Q · filed 2013-11-08 | $159.32K derived: sum of 2 quarters · filed 2013-11-08 | $228.94K 10-Q · filed 2013-11-08 | |||||||||
| 2012-06-30 | $69.62K 10-Q/A · filed 2013-09-06 | $139.23K 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |